Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
99340 trials found · Page 6 of 4967
-
Gene therapy offers hope for children with rare fatal brain disease
Disease control CompletedThis Phase I/II clinical trial consists of the application of lentiviral vector-based gene therapy to patients affected by Metachromatic Leukodystrophy (MLD), a rare inherited Lysosomal Storage Disorder (LSD) resulting from mutations in the gene encoding the Arylsulfatase A (ARSA…
Phase: PHASE1, PHASE2 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated May 27, 2026 11:48 UTC
-
New hope for kids with eye cancer: personalized therapy aims for cure and vision saving
⭐️ CURE ⭐️ CompletedRetinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain. When only one eye is affected, this is known as unilateral r…
Phase: PHASE3 • Sponsor: St. Jude Children's Research Hospital • Aim: ⭐️ CURE ⭐️
Last updated May 27, 2026 11:51 UTC
-
New drug combo aims to slow rare aging disease in kids
Disease control ENROLLING_BY_INVITATIONThis is a phase I/II dose-escalation trial of everolimus in combination with lonafarnib in Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies (henceforth "progeria"). The study will be conducted at a single clinical site utilizing the Clinical and Translation…
Phase: PHASE1, PHASE2 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
Gene therapy offers hope for boys with 'Bubble Boy' disease
Disease control CompletedX-linked severe combined immunodeficiency (SCID-X1) is an inherited disorder that results in failure of development of the immune system in boys. This trial aims to treat SCID-X1 patients using gene therapy to replace the defective gene.
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Ebola shield: new trial tests vaccine + antibody cocktail for High-Risk contacts
Prevention Not yet recruitingEBO-PEP is a multicentre, multi-epidemic, phase III, comparative, controlled, randomised, strict superiority trial in two unblinded parallel arms. The trial will be open during EVD epidemics and will recruit asymptomatic participants at high risk of developing EVD. Participants…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Prevention
Last updated May 18, 2026 12:03 UTC
-
Breakthrough TB cocktail cures Drug-Resistant cases in just 6 months
Disease control CompletedThe purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of bedaquiline plus PA-824 plus linezolid after 6 months of treatment (option for 9 months for participants who remain culture positive at month 4) in participants with either pulmona…
Phase: PHASE3 • Sponsor: Global Alliance for TB Drug Development • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Pig kidney trial offers new hope for kidney patients on long waitlists
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation…
Phase: PHASE1, PHASE2 • Sponsor: United Therapeutics • Aim: Disease control
Last updated May 26, 2026 12:09 UTC
-
Could three old drugs finally cure HIV? new trial aims to find out
⭐️ CURE ⭐️ Not yet recruitingThe PLUTO trial aims to contribute to the worldwide search for a functional cure of HIV. One the strategies ("shock and kill' strategy) aims to reverse the HIV-reservoir from latency by increasing cell-associated HIV-RNA, which will lead to increased antigen presentation, trigger…
Phase: PHASE1, PHASE2 • Sponsor: Erasmus Medical Center • Aim: ⭐️ CURE ⭐️
Last updated May 30, 2026 13:50 UTC
-
Fetal balloon procedure aims to save babies with rare birth defect
Disease control Not yet recruitingThe purpose of this study is to evaluate the safety and efficacy of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in cases of severe Congenital Diaphragmatic Hernia (CDH).
Phase: PHASE3 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated May 26, 2026 12:09 UTC
-
Hepatitis b cure hope: new study targets virus clearance in 10,000 patients
⭐️ CURE ⭐️ Not yet recruitingThis is a real-world, prospective, multicenter, non-randomized, controlled study. It aims to investigate the efficacy and safety of pegylated interferon α-2b (PEG IFN α-2b) monotherapy versus its combination with nucleos(t)ide analogs (NAs) regarding hepatitis B surface antigen (…
Sponsor: xieqing • Aim: ⭐️ CURE ⭐️
Last updated May 26, 2026 11:09 UTC
-
MRNA vaccine shows promise in preventing lung cancer recurrence in major new trial
Disease control Recruiting nowThe goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary h…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 12:00 UTC
-
Breakthrough CAR-T therapy aims to keep myeloma at bay without transplant
Disease control OngoingThe purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newl…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 12:02 UTC
-
New combo therapy shows promise against aggressive breast cancer
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC). After…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 12:03 UTC
-
New HIV prevention pill shows promise in large global trial
Prevention OngoingThe primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) with a mi…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated May 26, 2026 12:03 UTC
-
New hope for older leukemia patients: targeted radiation before transplant shows promise
Disease control Not yet recruitingThis phase II trial tests the effect of total marrow and lymphoid irradiation (TMLI) in combination with fludarabine and melphalan as conditioning regimen in older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has not responded to previous treatm…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 27, 2026 23:05 UTC
-
New combo approach targets limited-spread breast cancer: surgery plus radiation may extend life
Disease control Not yet recruitingThis phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therap…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 26, 2026 11:59 UTC
-
Engineered immune cells take on tough T-Cell cancers in new trial
Disease control Not yet recruitingTo determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
Could a single dose of oxfendazole cure brain parasites?
⭐️ CURE ⭐️ Not yet recruitingThe goal of this clinical trial is to compare a single and multiple dose regimens of oxfendazole with the standard treatment in patients with mild (one or two lesions) parenchymal brain cysticercosis. The main question it aims to answer is if OXF will enhance clearance of brain p…
Phase: PHASE2, PHASE3 • Sponsor: Universidad Peruana Cayetano Heredia • Aim: ⭐️ CURE ⭐️
Last updated May 27, 2026 11:51 UTC
-
New Five-Drug cocktail targets tough myeloma
Disease control Not yet recruitingThis study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem …
Phase: PHASE1, PHASE2 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New brain cancer wafer shows promise in aggressive tumor trial
Disease control Not yet recruitingThis study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma. Cerebraca Wafer is intended for use in recurrent glioblastoma as an adjunct to surgery (followed by standard-of-care temozol…
Phase: PHASE2, PHASE3 • Sponsor: Everfront Biotech Co., Ltd. • Aim: Disease control
Last updated May 27, 2026 11:48 UTC